The comparative use-result survey of TORAYMYXIN (PMX) for acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2032250211

Enrollment

760

Registered

2025-07-04

Start date

2024-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with AE-IPF who receive PMX treatment for the first time

Exclusion criteria

Exclusion criteria: Patients with AE-IPF who have previously received PMX treatment

Design outcomes

Primary

Measure	Time frame
Survival rate on 4 weeks after AE-IPF	—

Secondary

Measure	Time frame
1. Survival rate on 12 weeks after AE-IPF (compared to non-PMX treatment patients) 2. Improvement in pulmonary oxygenation (P/F ratio, AaDO2) before and after PMX treatment 3. Improvement of imaging findings in chest X-ray and high-resolution CT (HRCT) 4. Change in serum lactate dehydrogenase (LDH) levels before and after PMX treatment 5. Change in serum C-reactive protein (CRP) levels before and after PMX treatment 6. Duration of mechanical ventilation 7. Change in serum levels of KL-6, SP-D, ferritin, and D-dimer before and after PMX treatment 8. Comparison of efficacy between AE-IPF patients with and without a known triggers	—

Measure

Time frame

1. Survival rate on 12 weeks after AE-IPF (compared to non-PMX treatment patients) 2. Improvement in pulmonary oxygenation (P/F ratio, AaDO2) before and after PMX treatment 3. Improvement of imaging findings in chest X-ray and high-resolution CT (HRCT) 4. Change in serum lactate dehydrogenase (LDH) levels before and after PMX treatment 5. Change in serum C-reactive protein (CRP) levels before and after PMX treatment 6. Duration of mechanical ventilation 7. Change in serum levels of KL-6, SP-D, ferritin, and D-dimer before and after PMX treatment 8. Comparison of efficacy between AE-IPF patients with and without a known triggers

—

Contacts

Public ContactSeigo Takamatsu

Toray Industries, Inc.

device-safety.toray.mb@mail.toray+81-3-3245-8617

Outcome results